LENZ Therapeutics, Inc. (LENZ)
3.20
-0.30
(-8.57%)
USD |
NASDAQ |
Nov 18, 16:00
3.21
+0.01
(+0.31%)
After-Hours: 20:00
LENZ Therapeutics Debt to Equity Ratio : 0.0024 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 0.0024 |
| June 30, 2026 | 0.0026 |
| March 31, 2026 | 0.0027 |
| December 31, 2025 | 0.0029 |
| September 30, 2025 | 0.0049 |
| June 30, 2025 | 0.0051 |
| March 31, 2025 | 0.0062 |
| December 31, 2024 | 0.0068 |
| September 30, 2024 | 0.0073 |
| June 30, 2024 | 0.0088 |
| March 31, 2024 | 0.003 |
| December 31, 2023 | 0.0065 |
| Date | Value |
|---|---|
| September 30, 2023 | 0.2603 |
| June 30, 2023 | 0.2389 |
| March 31, 2023 | 0.0164 |
| December 31, 2022 | 0.0196 |
| September 30, 2022 | 0.0221 |
| June 30, 2022 | 0.0242 |
| March 31, 2022 | 0.0282 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.0237 |
| June 30, 2021 | 0.00 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| EyePoint, Inc. | 0.2005 |
| Ligand Pharmaceuticals, Inc. | 1.200 |
| Bristol Myers Squibb Co. | 1.915 |
| Context Therapeutics, Inc. | 0.0067 |
| Neumora Therapeutics, Inc. | 2.888 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 209.75M |
| Total Liabilities (Quarterly) | 17.75M |
| Shareholders Equity (Quarterly) | 192.00M |
| Current Ratio | 11.66 |
| Net Debt Paydown Yield | 0.10% |